Prof Fujie Zhang is the Director of AIDS Clinical and Research Centre, Capital Medical University, and a member of the WHO Committee on Antimicrobial Resistance. He is also the Head of the AIDS Expert Group, National Health Committee, and Associate Director of National Health Standards Committee for Infectious Diseases.

Prof Zhang has been engaged in teaching, clinical and research of infectious diseases for several decades. He is the pioneer conducted antiretroviral treatment (ART) for HIV/AIDS in Mainland China, and introduced and led the free ART, which is benefiting over 1.06 million patients.

As the PI, he conducted the first clinical trial of the anti-COVID small molecule drug (azfuridine), AIDS key projects of China 11th, 12th, and 13th Five-Year Plan, projects funded by the Ministry of Science and Technology of China, and the National Institutes of Health of the United States.

He has published more than 200 papers in journals such as the Lancet, with a citation exceeding 5390 and an h-index of 34. In 2021, he was awarded as the “Advanced Individual” in the national science and technology system in combating the COVID-19 pandemic by the Ministry of Science and Technology, China. He has also been honoured six times of provincial and ministerial-level awards and won the first prize in technical invention in Henan Province.